Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2020 Jul 20

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Pediatrica 2020 Jul 20

DOI: 10.23736/S0026-4946.20.05993-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

An update on biological therapies for pediatric allergic diseases

Riccardo CASTAGNOLI, Maria DE FILIPPO, Martina VOTTO, Alessia MARSEGLIA, Lorenza MONTAGNA, Gian Luigi MARSEGLIA , Amelia LICARI

Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy


PDF


Allergic diseases represent a global health burden. Patients with allergic diseases may experience disability, reduced quality of life and productivity, emotional distress, and social restrictions, in particular in the most severe cases. Current advances in unveiling the pathogenesis of allergic disorders have paved the way for the development of novel therapeutic strategies. Biological drugs have been widely studied in pediatric allergic asthma, with strong evidence of efficacy and safety. Moreover, promising results derive from studies on other conditions such as atopic dermatitis, chronic spontaneous urticaria, and food allergy. The review analyzes recent evidence on the role of biologic therapies for allergic diseases, focusing on the pediatric age.


KEY WORDS: Children; Biologics; Allergic diseases; Asthma; Chronic spontaneous urticaria; Atopic dermatitis; Food allergy

top of page